Oestrogen receptors and antioestrogen treatment of hormone-dependent tumours

PDF
Published: Jan 31, 2018
DOI: https://doi.org/10.12681/jhvms.15752
N. G. KOSTOMITSOPOULOS (Ν.Γ. ΚΩΣΤΟΜΗΤΣΟΠΟΥΛΟΣ)
Laboratory of Experimental Surgery and Surgical Research "NS Christeas' School of Medicine, University of Athens
Abstract

The oestrogen receptor is a ligand-activated transcription factor that modulates specific gene expression by binding to short DNA sequences. The study of the role of oestrogen receptor on the expression of the mitogenic actionof oestrogens and oncogenesis lead biomedical research in new approaches of the treatment of oestrogen-dependent tumors by using antioestrogens. Main mechanism of action of antioestrogens is the prevention of oestrogen action by blocking the binding of oestradiol to the oestrogen receptor. Tamoxifen, the most wellknown antioestrogen, is widely used as adjuvant therapy in all stages of human breast cancer. Recently interest is focused on the potential use of "pure" antioestrogens. The use of antioestrogens in veterinary oncology is also under discussion.

Article Details
  • Section
  • Review Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

· Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

· Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

· Authors are permitted and encouraged to post their work online (preferably in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Downloads
Download data is not yet available.
References
Beatson GT. On the treatment of inoperable cases in carcinoma of the mamma: suggestion for new method of treatment illustrative cases. Lancet 1896, 2:104-107
…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………
Powcis Ti, Jones Ai., Ashley SE, O'Brien MER, Tid> VA, Treieavên J, Cosgrove D, Nash AG. Sacks N, Baum McKinna JA. DaveyJB. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer ResTreal 1994,31:73-82
Robertson DW, Katzenellenbogen JA, Long DJ, Roi : Katzenellenbogen BS. Tamoxifen antiestrogen. A comparison of the activity, pharmacokinetics and metabolic activation of the eis- and trans- isomers of tamoxifen, J Steroid Biochem 1982, 16:1-13
Rochefort H, Borgna JL, Evans E. Cellular and molecular mechanism of action of antiestrogens. J Steroid Biochem 1983, 19:69-74
Morris JS, Dobson JM. BostóckDE. Use of t amoxi fen in the control of canine mammary neoplasia. Vet Ree 1993, 133:539-542
Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984, 36:245-275
Ruben J. Use of tamoxifen in control of canine mammary neoplasia. Vet Ree 1993, 133:602
Baker RW. Use of tamoxifen in the control of canine mammary neoplasia. Vet Ree 1994, 134:2 !
Hemminki K, Widlak P, Hon SM. DNA adducis caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 1995,16:1661-1664
Osborne CK. Mechanisms of tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism J Steroid Biochem Molec Biol 1993,47:83-89
DeCupis A, Nooman D, Pirani P, Ferrera A, Clerico L, Favoni RE. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-1-induced proliferation of human breast cancer-derived ceils. Br J Pharmacol L995J 16:2391-2400
Jordan VC. Molecular mechanisms of antiestogen action in breast cancer. Breast Cancer Res Treat 1994,31:41 -52
Toft D, Shyamala Ci, Gorski J. A receptor molecu estrogens: studies using a cell-free system. Proc Natl Acad Sci USA 1967,57:1740-1743
Skidmore JR, Walpole AL. Woodburn J. Effect oï some triphenyieihylenes on estradiol binding in Miro to maeromolecules from uterus and anterior pituitary, J
Endocrinol 1972,52:289 . 98
Binari Ν, Catelli ΜΗ, Greynot C, Pun V, Hehnei R. Mester J, Baulieu EE. Monohydroxy-tamoxifen: an antiestr« •••_.• n w il :ί high affinity for the chick oviduct estrogen receptor. Biochem Biophys Res Commun 1979, 91 :S 12-818
Croxtail JD, Emmas C, White JO, Choudhary Q Flave! $}. Tamoxifen inhibits growth oi estrogen receptor-negative A549 cells. Biochem Pharmacol 1W. 47:197-202
Daniel CP, Gaskeil SJ, Nicholson Rl. The measurement of tamoxifen and metabolites in die rat and relationship to the response of DMBA-induced mammary tumours Eui J Cancer Clin Oncol 1984, 20:137-143
Sunderland MC, Osborne CK. Tamoxifen in premenopausal patient with metastatic breast cancer: a review. J < 1991,7:1283-1297
Robinson SP, Jordan VC. Reversal of antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene- induced rat mammary carcinoma model. Cancer Res 1987,47:5386-5390
Jordan VC, Gottardis MM, Robinson SP, Field A. Immune deficient animals to study "hormone-dependent" breast cancer and endometrial cancer. J Steroid Biochem 1989, 34:169-176
Kon OL. An antiestrogen-binding protein in human tissues. J BiolChem 1983,258:3173-3177
Musgrove EA, Wakeling AE, Sutherland RL. Points ofestrogen antagonists and a calmodulin antagonist within MCF-7 human breast cancer cell cycle. Cancer Res 1989, 49:2398-2404
Kroeger EA, Brandes LJ. Evidence that tamoxifen is an histamine antagonist. Biochem Biophys Res Commun 1985, 131:750-755
Tavares IA, Stamford IF, Bennet A. Tamoxifen inhibits 5-lipoxygenase in human polymorphonuclear lymphocytes. J Pharm Pharmacol 1987, 39:323-324
O'Brien CA, Liskamp RM, Solomon DH, Weinstein IB. Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 1986, 76:1243-1246
Mandeville R, Ghali SS, Chausseau JP. In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Eur J Cancer Clin Oncol 1984, 20:983-985
Roche ion H, Lign α F. < apon F. Formation of estrogen nuclear receptor in the uterus: effect of androgens, estrone and nafoxidine. Biochem Biophys Res Commun 1972, 47:662-670
Clark JH. Anderson JN, Peck EJ. Estrogen receptorantiestrogen complex: atypical binding by uterine nuclei and effects on uterine growth, steroids 1973,22:707-718
Pavlik EJ, Nelson K. van Nagel! JRJr. Donaldson ES, Waiden ML. Hanson MB. Gallion H, Flanigan RC, Kenady DE. Hydrodynamic characterization of estrogen receptor complexes with [lH)-4-hydroxytamoxifen: evidence in support of contrasting receptor transitions mediated by different ligands. Biochemistry 1985.24:8101-8106
Pavlik EJ, von Nagell JRJr. Nelson K, Gallion H, Donaldson ES, Kenady DE. Baranowska-Kortylewicz J. Antagonism to estradiol in the mouse: reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg, : -soluble chromatin fraction. Endocrinology 1986, 118:1924-1934
Metzger D, White JH, Chambon P. The human oestrogen receptor functions in yeast. Nature 1988,334:31-36
Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen. EMBO J 1990,9:2811-2818
Wakeling AE. Are breast tumours resistant to tamoxifen also resistant to pure antiestrogens? J Steroid Biochem Molec Biol 1993,47:107-114
Most read articles by the same author(s)